There are currently no reports of the effect of combinatorial therapy using tyrosine kinase inhibitors with anti-PD-1/PD-L1 immunotherapy for the treatment of pancreatic cancer. This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.